tasimelteon
VP-VEC-162-2401
Phase 3 small_molecule completed
Quick answer
tasimelteon for Smith-Magenis Syndrome is a Phase 3 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vanda Pharmaceuticals
- Indication
- Smith-Magenis Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed